Results 141 to 150 of about 371,644 (221)

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

Einstein (Sao Paulo)
Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, Serrano Usón Junior PL, Kaliks R, Beal JR.   +8 more
europepmc   +1 more source

Liposomal Nanoconfinement Enables Type I Photodynamic Conversion for Synergistic Cancer Photothermal‐Immunotherapy

Advanced Science, EarlyView.
Liposomal nanoconfinement converts the hemicyanine photosensitizer RhM from Type‐II to Type‐I photodynamic therapy (PDT) while enhancing photothermal therapy (PTT). The RhM‐R837@Lip nanoassembly efficiently generates superoxide (O2•−) and hydroxyl radicals (•OH) to kill tumor cells and achieve tumor ablation.
Minglu Zhang, Shanshan Liang, Meng Wang, Tingfeng Zhang, Jinke Liu, Yuyuan Peng, Hao Fang, Lingna Zheng, Xiao He, Meng Wang, Luling Wu, Tony D. James, Wei Zhao, Bing Wang, Weiyue Feng   +14 more
wiley   +1 more source

HER destiny too

Translational Cancer Research, 2023
openaire   +2 more sources

HER2 expression in breast cancer: evidence gaps and challenges. [PDF]

NPJ Precis Oncol
Atallah NM, Quinn C, Rakha E.
europepmc   +1 more source

China’s Manifest Destiny [PDF]

, 2018
de Burgh, H., de Burgh, H.
core  

Timing Mechanotransduction: Mechanically Dynamic Biomaterials Reveal the Temporal Hierarchy of YAP/TAZ Control Nodes

Advanced Science, EarlyView.
This work develops dynamically softening polyacrylamide hydrogels for time‐resolved imaging during continuous mechanical transitions. The study revealed that mechanotransduction is biphasic; YAP/TAZ inactivation is driven by early loss of the nucleocytoskeletal continuum connecting subnuclear adhesions, F‐actin, and the nuclear envelope, coupled with ...
Alessandro Gandin, Giada Vanni, Veronica Torresan, Margherita Pelosin, Rebecca Busetto, Anna Citron, Ambela Suli, Paolo Contessotto, Carlo Albanese, Francesca Zanconato, Tito Panciera, Stefano Piccolo, Giovanna Brusatin   +12 more
wiley   +1 more source

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.

JAMA Netw Open
Jänne PA, Planchard D, Goto K, Smit EF, de Langen AJ, Goto Y, Ninomiya K, Kubo T, Pérol M, Felip E, Hayashi H, Nakagawa K, Shimizu J, Nagasaka M, Pereira K, Taguchi A, Ali A, Karnoub M, Yonemochi R, Leung D, Li BT.   +20 more
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Antibody-drug conjugates in HER2-positive advanced or metastatic gastric cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Li J, Chen S, Chai Y, Qiu S.
europepmc   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source